EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant

Jéssica P Farias, Josilene R Pinheiro, Robert Andreata-Santos, Mayanna M C Fogaça, Ruth D da Silva Brito, Edgar F da Cruz, Maria F de Castro-Amarante, Samuel S Pereira, Shirley Dos Santos Almeida, Ludimila M Moreira, Rafael da Conceição Simões, Wilson B Luiz und 8 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Jéssica P Farias und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras, Brazil. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministério da Ciência, Tecnologia e Inovação, Financiadora de Estudos e Projetos, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main coronavirus disease 2019 (COVID‐19) vaccine formulations used today are mainly based on the wild‐type severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein as an antigen. However, new virus variants capable of escaping neutralization activity of serum antibodies elicited in vaccinated individuals have emerged. The Omicron (B.1.1.529) variant caused epidemics in regions of the world in which most of the population has been vaccinated. In this study, we aimed to understand what determines individual's susceptibility to Omicron in a scenario of extensive vaccination. For that purpose, we collected nasopharynx swab ( n = 286) and blood samples ( n = 239) from flu‐like symptomatic patients, as well as their vaccination history against COVID‐19. We computed the data regarding vaccine history, COVID‐19 diagnosis, COVID‐19 serology, and viral genome sequencing to evaluate their impact on the number of infections. As main results, we showed that vaccination in general did not reduce the number of individuals infected by Omicron, even with an increased immune response found among vaccinated, noninfected individuals. Nonetheless, we found that individuals who received the third vaccine dose showed significantly reduced susceptibility to Omicron infections. A relevant evidence that support this finding was the higher virus neutralization capacity of serum samples of most patients who received the third vaccine dose. In summary, this study shows that boosting immune responses after a third vaccine dose reduces susceptibility to COVID‐19 caused by the Omicron variant. Results presented in this study are useful for future formulations of COVID‐19 vaccination policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesHumansAntibodies, NeutralizingAntibodies, ViralCOVID-19 TestingSARS-CoV-2Spike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID-19antibodyneutralizationvaccination policyvaccine doses

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras, Brazil.
  • Department of Biological Sciences, State University of Santa Cruz, Ilhéus, Brazil.
  • Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
  • Division of Infectology, Medicine Department, Federal University of São Paulo, São Paulo, Brazil.
  • Vaccine Development Laboratory, Microbiology Department, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
  • Scientific Platform Pasteur USP, University of São Paulo, São Paulo, SP, Brazil.

Förderung

  • Ministério da Ciência, Tecnologia e Inovação
  • Financiadora de Estudos e Projetos
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Instituto Serrapilheira

Zitieren

APA

Farias, J. P., Pinheiro, J. R., Andreata-Santos, R., Fogaça, M. M. C., da Silva Brito, R. D., da Cruz, E. F., de Castro-Amarante, M. F., Pereira, S. S., Dos Santos Almeida, S., Moreira, L. M., da Conceição Simões, R., Luiz, W. B., Birbrair, A., Belmok, A., Ribeiro, B. M., Maricato, J. T., Braconi, C. T., de Souza Ferreira, L. C., Janini, L. M. R., & Amorim, J. H. (2023). The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant. Journal of Medical Virology. https://doi.org/10.1002/jmv.28481

Vancouver

Farias JP, Pinheiro JR, Andreata-Santos R, Fogaça MMC, da Silva Brito RD, da Cruz EF, et al. The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant. Journal of Medical Virology. 2023. doi:10.1002/jmv.28481

BibTeX
@article{Farias2023,
  author = {Farias, Jéssica P and Pinheiro, Josilene R and Andreata-Santos, Robert and Fogaça, Mayanna M C and da Silva Brito, Ruth D and da Cruz, Edgar F and de Castro-Amarante, Maria F and Pereira, Samuel S and Dos Santos Almeida, Shirley and Moreira, Ludimila M and da Conceição Simões, Rafael and Luiz, Wilson B and Birbrair, Alexander and Belmok, Aline and Ribeiro, Bergmann M and Maricato, Juliana T and Braconi, Carla T and de Souza Ferreira, Luís C and Janini, Luiz M R and Amorim, Jaime Henrique},
  title = {The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS‐CoV‐2 variant},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28481}
}
Kostenlos starten →